Both 2nd and 3rd doses on time

"Both 2nd and 3rd doses on time" refers to the standard, recommended dosing schedule of the recombinant quadrivalent human papillomavirus (HPV) vaccine (Gardasil). This schedule was evaluated in a prospective observational study conducted by Duke University ("Alternate Dosing Schedules Study for HPV Vaccine", NCT02280642). The study compared the immunogenicity (antibody titers and avidity) of this standard on-time dosing schedule (where the second dose is given 1-2 months after the first, and the third dose is given 6 months after the first) against various delayed dosing schedules in healthy girls aged 9 to 18. The underlying quadrivalent vaccine targets the L1 major capsid proteins of HPV types 6, 11, 16, and 18 to prevent cervical cancer, genital warts, and other HPV-associated lesions.